Noveldx
3 known investors
Find your way into Noveldx
Novel Microdevices develops a portable, battery-powered point-of-care molecular diagnostic system that runs PCR-based nucleic acid amplification on disposable cartridges to detect pathogens and antibiotic-resistance mutations in about 15 minutes. The system targets same-visit testing and diagnosis, with an emphasis on low-resource settings and low- and middle-income countries.
Founders & leadership
AP
Andrea PaisinCEO, Co-Founder
RP
Rohan PaisinVP, Engineering, Co-Founder
CA
Carlos AparicioinChief Operating Officer
Investors · 3
Competitors · 5
by search overlap
Foresight Diagnostics6 shared keywordsForesight Diagnostics develops ultra-sensitive molecular diagnostic tests that combine genomics and bioinformatics to detect minimal residual disease and circulating tumor DNA across multiple cancer types. Its offerings support oncology drug development, clinical trials, and patient care for academic and biopharma partners.
Molecular Devices6 shared keywordsMolecular Devices provides automated systems and services to support 3D cell biology research workflows, including cell culture automation, organoid expansion services, and imaging analysis tools for drug discovery and preclinical research.
Labcorp5 shared keywordsLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.
AmplifiDx4 shared keywordsAmplifiDx develops point-of-care molecular diagnostic tests and its DX 100 platform for family, women's, and sexual health, targeting infectious disease detection for healthcare professionals and patients. The multiplex platform can detect up to 10 analytes with rapid results and minimal hands-on time.
Galaxy Diagnostics4 shared keywords
Companies competing with Noveldx for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Noveldx do?
- Novel Microdevices develops a portable, battery-powered point-of-care molecular diagnostic system that runs PCR-based nucleic acid amplification on disposable cartridges to detect pathogens and antibiotic-resistance mutations in about 15 minutes. The system targets same-visit testing and diagnosis, with an emphasis on low-resource settings and low- and middle-income countries.
- Who founded Noveldx?
- Noveldx was founded by Andrea Pais, Rohan Pais.
- Who are Noveldx's investors?
- Noveldx's investors include Maryland TEDCO, Old Line Capital Partners, TEDCO.